Prostate Specific Antigen News and Research

RSS

Obesity is linked to lower levels of prostate specific antigen (PSA) in men

A study reported in the current issue of Cancer, the journal of the American Cancer Society, shows that obesity is linked to lower levels of prostate specific antigen (PSA) in men, making early detection tests unreliable.

24 Jan 2005

European approval for Taxotere (docetaxel) in prostate cancer

Aventis, part of the sanofi-aventis Group announced today that the European Commission has approved Taxotere (docetaxel) Injection Concentrate for use in combination with prednisone as a treatment for men with androgen-independent (hormone- refractory) metastatic prostate cancer.

4 Nov 2004

Study aims to improve information and support for older men with prostate cancer

The Centre for Health Services Studies (CHSS) at the University of Kent, England is currently engaged in an exploratory study of the information and support needs for men aged 75+ with prostate cancer.

4 Nov 2004

Prostate cancer patients who no longer respond to hormone therapy may benefit from a combination of docetaxel and estramustine

Prostate cancer patients whose cancer has spread to other parts of the body and who no longer respond to hormone therapy may benefit from a combination of the cancer drugs docetaxel and estramustine, according to a new study published in the Oct. 8 issue of the New England Journal of Medicine.

8 Oct 2004

Breast cancer drug Taxotere extends life of prostate cancer patients

Men with androgen-independent (hormone-refractory) metastatic prostate cancer treated with the breast-cancer drug Taxotere (docetaxel) Injection Concentrate in combination with the drug estramustine survived 20 percent longer than similar patients receiving the standard therapy

6 Oct 2004

Lycopene may be able to inhibit the growth of prostate tumours

A study by Dutch and German researchers has provided evidence that lycopene may be able to inhibit the growth of prostate tumours and that its effect may be enhanced if it is combined with vitamin E.

30 Sep 2004

Black men in the United States are significantly less likely to be screened for prostate cancer

Although black men in the United States are more likely than white men to be diagnosed with advanced prostate cancer and have a two-fold greater risk of dying from it, they are significantly less likely to be screened for prostate cancer

29 Sep 2004

Elderly African American men are less likely to get tested for prostate cancer

Elderly African American men are less likely to get tested for prostate cancer than elderly white men, according to an article in the September 27 issue of the Archives of Internal Medicine, one of the JAMA/Archives journals.

26 Sep 2004

Researchers have discovered a possible way to distinguish lethal from localized prostate cancers

If future studies show their test -- measuring the level of activity of a signaling pathway called Hedgehog -- can predict which prostate cancers will spread, the results could revolutionize decision making processes for prostate cancer patients, the researchers say.

13 Sep 2004

PSA test is now all but useless for predicting prostate cancer risk

The PSA test, commonly used as a screening tool for detecting prostate cancer, is now all but useless for predicting prostate cancer risk, according to Stanford University School of Medicine researchers.

10 Sep 2004

Study reveals what may be the earliest step in the development of prostate cancer

The finding could open the door to new tests that predict whether the cancer will become aggressive and the development of treatments to prevent the condition from progressing.

2 Sep 2004

Combination therapies improve prostate cancer survival rates

The addition of six months of androgen suppression therapy (AST) to radiation therapy improves survival of patients with clinically localized prostate cancer, according to a study in the current issue of the Journal of the American Medical Association.

18 Aug 2004

Combination of hormonal therapy, radioactive seed implant and external beam radiation therapy increases chance of cancer cure

High-risk prostate cancer patients who undergo a combination of hormonal therapy, radioactive seed implant (also called brachytherapy) and external beam radiation therapy are shown to have an increased chance of cancer cure

29 Jul 2004

Stat5 protein is particularly plentiful in high histological grade human prostate cancer

Prostate cancer is much more likely to be aggressive if a key protein called Stat5 is found activated and in abundance in the cancer cells, report researchers from Georgetown University's Lombardi Comprehensive Cancer Center.

15 Jul 2004

Joint initiative to tackle cancer, diabetes, heart disease and stroke

Three of the nation’s leading not-for-profit health agencies today announced a joint initiative to empower Americans to help lower their risk of cancer, diabetes, heart disease and stroke by following a single set of recommendations.

16 Jun 2004

Docetaxel decreases the chance of dying by 24 percent in advanced-stage prostate cancer patients resistant to hormone therapy

Johns Hopkins Kimmel Cancer Center clinicians were among those at leading institutions that have completed a three-year international study showing that docetaxel, a drug made from yew tree needles, decreases the chance of dying by 24 percent in advanced-stage prostate cancer patients resistant to hormone therapy.

11 Jun 2004

Prostate cancer immunotherapy vaccine hits clinical trials

Scientists at the Austrlia's, Queensland Institute of Medical Research (QIMR) are currently trialing an experimental "immunotherapy" treatment for men with advanced prostate cancer.

10 Jun 2004

Non-aspirin pain drugs may help men with recurrent prostate cancer

Early results from a University of North Carolina at Chapel Hill School of Medicine study may determine if drugs called Cox-2 inhibitors, a newer type of non-aspirin pain medicine now widely prescribed for arthritis symptoms, may benefit men with recurrent prostate cancer.

10 Jun 2004

Lovastatin and Simvastatin have a significantly reduced risk of prostate cancer

Men who take even small amounts of common cholesterol-lowering drugs such as Lovastatin and Simvastatin have a significantly reduced risk of prostate cancer, according to a new study by Oregon Health & Science University Cancer Institute researchers.

9 Jun 2004

Current test for prostate cancer is inadequate

Britain’s top cancer scientists claim that men’s health is at risk because the current test for prostate cancer is inadequate. The warning comes as The Institute of Cancer Research launches the 7th Everyman Male Cancer Awareness Month to alert men to the risk of prostate and testicular cancer.

27 May 2004